Newsroom

Latest from Alvotech

Investor news

Request email alerts

Stay current with Alvotech news and developments. Receive investor announcements and updates as they go live.

SEC FilingsEventsNews

About Us
Media Center
Careers
Newsroom
Contact us

Terms of Use
Privacy Policy
Cookie Policy

Alvotech 2025. All rights reserved.

Company
For investors
Biosimilars
Corporate Sustainability
Careers

Year

Tag

Company Announcement

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Company Announcement

Alvotech to present at upcoming investor conferences in September

REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Company Announcement

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Financial Reports

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...

Company Announcement

Alvotech to Report Financial Results for H1 2026

REYKJAVIK, ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...

Company Announcement

Alvotech announces successful closure of FDA inspection of manufacturing facility

REYKJAVIK, ICELAND (July 29, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...

Managers’ Transactions

Transactions of Managers and Closely Associated Persons

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging...

Company Announcement

Alvotech further strengthens liquidity by securing term loan facility of $75 million

$75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset ManagementFollows recent $165m equity raise strengthening cash positionIncluding equity financing and...

Managers’ Transactions

Transactions of Managers and Closely Associated Persons

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition...

Company Announcement

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...

Inside information

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...

1 2 3 4…32